Icecure Medical Ltd. · NASDAQ:ICCM
Icecure Medical — Investor Presentation (March 2021)
33 slides from Icecure Medical's investor presentation, March 2021
Slide 1: Freezing Cancer in Its Tracks
FREEZING CANCER IN ITS TRACKS Next generation cryoablation technology enabling non‐surgical, in‐office treatment of cancer tumors Corporate Presentation | March 2021 ICCM (TASE) icecure-medical.com 1
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation does not constitute an offering to purchase or sale securities of IceCure Medical Ltd. ("the Company") or an offer to receive such offerings. The presentation's sole purpose is to provide information. This presentation was prepared by the Company. The info
Slide 3: Our Mission
OUR MISSION: To lead the New Gold Standard of Tumor Cryoablation Therapy 3 3
Slide 4: IceCure at a Glance
IceCure at a Glance… ProSense® Proprietary Technology with Regulatory Approval • FDA Approval for general minimally-invasive cryoablation applications, specific indications including: Kidney, Liver, Neurology, Fibroadenoma • CE Approval for benign or malignant tissue of: Breast, Lung, Musculoskeleta
Slide 5: Introducing ProSense: Non-surgical, Next-Gen Cryoablation Technology
Introducing ProSense®: Non-surgical, Next-Gen Cryoablation Technology • IceCure’s flagship product, ProSense®, is a minimally invasive, non-surgical solution that destroys tumors quickly and painlessly • Utilizing effective liquid nitrogen (LN2) for maximum freezing, safety and efficacy http://www.y
Slide 6: COVID-19 Driving ProSense Market Adoption
COVID-19 Driving ProSense® Market Adoption Surgery Delays, Cancellations Healthcare institutions urgently seek new solutions to: & Backlogs ✓ Reduce hospitalization & clinic visits There is a 6-8% increase in the risk of death for every four week delay in ✓ Reduce demands on Emergency Rooms tumor re
Slide 7: ProSense: Value for All
ProSense®: Value for All Patient Physician Insurer Healthcare Provider ✓ LN2* - Maximum Efficacy ✓ Easy to Use, In-office ✓ Lower Reimbursement ✓ Patient Demand Drives Procedure Expense Vs. Surgery Reimbursement ✓ Non-surgical ✓ Low Risk, Safe Procedure ✓ In-Office Procedure ✓ Faster, In-Office Proc
Slide 8: Market Opportunities
Market Opportunities Tumor Ablation US Cryoablation Tumor Ablation Market Expected To Reach Breast Tumors $2.4 Billion in 2026† 330K New breast cancer patients expected in 2021* 10% of female pop. est. to have fibroadenomas** $2.4 (CAGR) Potential B driven by Breast Cancer Breast Fibroadenoma non/mi
Slide 9: Rising Market Interest for Cryo-Based and Women Health Solutions
Rising Market Interest for Cryo-Based and Women Health Solutions $110 Million in 2016 $4.2 Billion in 2018 $16.4 Billion in 2020 Britain's BTG acquired Israeli tumor Boston Scientific Siemens Healthineers acquired Varian freezing company, Galil Medical acquired BTG Medical Systems (radiation oncolog
Slide 10: Breast Tumor Market Activities
BREAST TUMOR MARKET ACTIVITIES 10
Slide 11: Breast Cancer International Strategy
Breast Cancer International Strategy Europe Asia ✓ CE approval in EU ✓ Regulatory approvals for: Thailand, India, ✓ KOLs collecting clinical Singapore, Hong Kong, China (for system – data in Italy & Germany IceSense3 only, seeking approval for probes), & ✓ Netherlands others independent trial ✓ Ongo
Slide 12: Breast Cancer & Benign Tumors USA Strategy
Breast Cancer & Benign Tumors USA Strategy Regulatory strategy ✓ FDA clearance for general minimally-invasive cryoablation applications ✓ FDA clearance for fibroadenoma (benign breast tumors) cryoablation ✓ Completed ICE3 study enrollment, interim results expected 2021 Targeting FDA approval for bre
Slide 13: ICE3: Landmark US Breast Cancer Trial
Unique Value Proposition ICE3: Landmark US Breast Cancer Trial Largest USA controlled multicenter clinical trial ever performed for LN2 based cryoablation of small, low-risk, early stage malignant breast tumors as an alternative to surgery 206 19 60 3 Patients Patients treated Hospitals Patients Yea
Slide 14: Breast Cancer China Strategy
Breast Cancer China Strategy Regulatory strategy ✓ Console approved by CFDA ✓ Initiated a registration process for the consumable probes ✓ Approved in Hong Kong Go to market ✓ Soft launch – first consoles were sold in Dec 2019 for independent study for breast cancer to a leading breast cancer hospit
Slide 15: Breast Cancer Japan Terumo Agreement
Breast Cancer Japan Terumo Agreement Exclusive strategic distribution agreement with Terumo to accelerate commercialization of ProSense® in Japan, Singapore, and Thailand For >6 years ProSense® has been sold through a Private Import License—now leveraging agreement with Terumo to expand distribution
Slide 16: ProSense is Superior to Competing Thermal Ablation Technologies
ProSense® is Superior to Competing Thermal Ablation Technologies Cryoablation Thermal Ablation IceCure ProSense® (Radiofrequency & Microwave) Pain Minimal to no pain Very painful Anesthesia Local High amount to general Visualization Excellent contour under Ultrasound & CT Limited visualization Accur
Slide 17: ProSense: The Most Advanced Cryoablation Technology
ProSense®: The Most Advanced Cryoablation Technology Superior Liquid Nitrogen (LN2) Technology 3rd Generation 2nd generation 1st Generation IceCure Sanarus Visica Galil Medical for Optimal Tumor Destruction ProSense® 2™ EndoCare Tumor Destruction Method Liquid nitrogen Liquid nitrogen Argon gas Cons
Slide 18: Business Model – Revenue Generators
Business Model – Revenue Generators Console and consumable probe business model Direct sales and via distributors ✓ Direct sales to hospitals, clinics and doctor offices ✓ Reselling to distributors: ✓ Used as a mobile device in different hospitals, clinics, doctor offices in Europe Console related r
Slide 19: Well-financed to advance commercialization of ProSense
Well-financed to advance commercialization of ProSense® Dec 31, 2020 Cash Private placement of ordinary shares of $15M CASH balance of $8.7M • Subject to General Meeting approval- Private placement from three accredited investors (Alpha Capital Anstalt, 2020 rev of $3.9M, Clover Wolf and Clover Alph
Slide 20: Proven Leadership Team
Proven Leadership Team Ron Mayron, Chairman of the Board Shay Levav – VP Clinical, Regulatory & QA Served for 20 years in several positions at Nearly 20 years’ experience in regulatory and quality Teva including as VP – Israel & Africa & assurance in the healthcare sector CEO of Teva Israel Eyal Sha
Slide 21: Why Invest in IceCure?
Why Invest in IceCure? Exclusive distribution Well positioned for Collaboration with FDA and CE ASBrS for registry agreement with Cleared future BC specific Terumo Corporation commercialization trial and update of ICE3 Trial guidelines Wide Market Excellent Patient Superior LN2 Successful transition
Slide 22: Thank You
PROSENSE® FREEZE CANCER IN ITS TRACKS THANK YOU Eyal Shamir – CEO E: eyals@Icecure-medical.com Ronen Tsimerman – CFO\COO E: ronent@Icecure-medical.com T: 972-4-623-0333 22
Slide 23: Appendices
Appendices Interventional Radiology Fibroadenoma 23 23
Slide 24: IceCure's Target Geographies & Markets
IceCure’s Target Geographies & Markets USA* Europe**** Japan*** 86K New breast 523K New breast 42K 74K 330K 226K 531K cancer patients in 71K cancer 2018 92Kpatients in 139K Liver cancer patients Kidney cancer New breast cancer 2018 Kidney & liver New breast Kidney & liver New breast Lung cancer pati
Slide 25: Interventional Radiology
Interventional Radiology Pain care for bone cancer metastasis 431K worldwide kidney cancer cases in 2020* (CAGR of 2.4%) CPT2 reimbursement in the USA CE approval, actively being used for • Ongoing trial and collaborative procedures in EU clinical research in Israel • FDA approval for kidney and liv
Slide 26: Interventional Radiology: Expanding Product Line
Interventional Radiology: Expanding Product Line Over 500,000 new people each year are diagnosed with kidney, lung, liver and prostate cancer in the U.S. alone! >2.5M new cases of lung 478K new cases of kidney cancer globally by 2025 cancer globally by 2025 vs. 2M in 2018 (CAGR of 1.8%). vs. 403K in
Slide 27: Interventional Radiology USA Regulatory Status
Interventional Radiology USA Regulatory Status Reimbursement – CPT* ✓ FDA approval for general minimally- ✓ CPT 1 approval and coverage for invasive cryoablation applications Cryo treatments of kidney, liver, lung & bone ✓ FDA approval for kidney and liver, as of Dec 2019 *CPT or Current Procedure T
Slide 28: Renal Cancer: Ongoing Trial and Collaborative Clinical Research, Israel
Renal Cancer: Ongoing trial and collaborative clinical research, Israel Results presented at 2019 EAU 120 PATIENTS With 139 small kidney masses View full Poster (≤ 4cm) treated 93% Lack of enhancement Results published in 2019 in on CT or MRI in (42 of 45) of cases at 1 year follow-up. Investigators
Slide 29: Bone Cancer Palliative Treatment
Bone Cancer Palliative treatment Reducing pain in less than 10 minutes: ITALY SPAIN FRANCE One of the most important benefits coming from the last two years using IceCure cryoablation among the older ablation devices is that the treatment is completely unpainful. It means that usually the patient do
Slide 30: Lung Cancer: Ongoing Independent Trial in Japan
Lung Cancer: Ongoing Independent Trial in Japan >300 PATIENTS Results published in 2019 in Treated to date 100% Overall survival rate after ProSense® therapy vs. ~78% after View full Publication radiation at three-year follow-up on ~30 T1mi +T1a +T1b cancer patients (<2cm mass) Led by Dr. Hiroaki No
Slide 31: Support from Experts
Support from Experts: “I have been using the ProSense® system for all my cryoablation procedures for the past year. I have plenty of experience using the typical argon-based systems – and IceCure offers several advantages over those systems. First, the rate of freeze is much faster. We know from stu
Slide 32: ICE3 is Changing the Treatment Landscape
ICE3 is Changing the Treatment landscape American Society of Breast Surgeons (ASBrS) Oct 2018 Guidelines: “Cryoablation is currently approved for treatment of benign and malignant soft tissue tumors. FDA. Currently, there are no specific technologies that have FDA approval for breast tumors. Partici
Slide 33: ProSense: Becoming the Gold Standard in Fibroadenoma Therapy
ProSense®: Becoming the Gold Standard in Fibroadenoma Therapy Treating 60 patients fibroadenomas who underwent successfully since office-based clinical trials treatment reported: (ProSense® cryoablation treatment began in 2012 under ultrasound guidance) Minimally invasive, in-office Lesions tended t